Liza C. Villaruz, MD, assistant professor of medication, Division of Hematology/Oncology, College of Pittsburgh, discusses PD-L1 expression in lung most cancers.The extent of PD-L1 expression is crucial issue within the number of immunotherapy for sufferers with lung most cancers, says Villacruz. For sufferers who’ve an overexpression of PD-L1 of their tumors, Villacruz says that she normally prescribes single-agent pembrolizumab (Keytruda). That is as a result of important response charges of about 45%, however that fee of response might be elevated with the addition of chemotherapy.This comparability must be taken with a grain of salt, Villacruz says, as the info with pembrolizumab and the info with pembrolizumab plus chemotherapy haven’t been studied head-to-head. With that being stated, Villacruz says that in sufferers who categorical lower than 50% PD-L1, her normal of care is pembrolizumab plus chemotherapy. For sufferers who overexpress PD-L1, pembrolizumab monotherapy remains to be Villacruz’s first alternative.